Advertisement

The Pathogenesis of Anaplastic Large Cell Lymphoma

  • Suzanne Dawn TurnerEmail author
Chapter

Abstract

Cancers of childhood differ from those of adulthood on a number of levels and are generally associated with fewer genetic alterations. Indeed, many are driven by known, key genomic events, translocations being predominant. When and where these events take place are largely unknown, but the paediatric presentation is suggestive of events early in life, even perhaps in utero. Anaplastic large cell lymphoma (ALCL) presents an excellent paradigm of the origins and pathogenesis of childhood cancer being largely associated with translocations creating hyperactive anaplastic lymphoma kinase (ALK) fusion proteins posited to occur in primitive haemopoietic cells, ultimately presenting in the periphery with a disease phenotype perhaps shaped by normal T cell activities.

Keywords

Anaplastic large cell lymphoma (ALCL) T cell lymphoma Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) Paediatric lymphoma Lymphoma origins Lymphoma pathogenesis 

References

  1. 1.
    Minard-Colin V, Brugieres L, Reiter A, Cairo MS, Gross TG, Woessmann W, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol. 2015;33(27):2963–74.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Turner SD, Lamant L, Kenner L, Brugieres L. Anaplastic large cell lymphoma in paediatric and young adult patients. Br J Haematol. 2016;173(4):560–72.PubMedGoogle Scholar
  3. 3.
    Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–4.PubMedGoogle Scholar
  4. 4.
    Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001;20(40):5623–37.PubMedGoogle Scholar
  5. 5.
    Damm-Welk C, Klapper W, Oschlies I, Gesk S, Rottgers S, Bradtke J, et al. Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation. Br J Haematol. 2009;146(3):306–9.Google Scholar
  6. 6.
    Perkins SL, Pickering D, Lowe EJ, Zwick D, Abromowitch M, Davenport G, et al. Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: a genetic and pathological correlation. Br J Haematol. 2005;131(5):624–7.PubMedGoogle Scholar
  7. 7.
    Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126(1):17–25.PubMedGoogle Scholar
  8. 8.
    Ye X, Shokrollahi K, Rozen WM, Conyers R, Wright P, Kenner L, et al. Anaplastic large cell lymphoma (ALCL) and breast implants: breaking down the evidence. Mutat Res Rev Mutat Res. 2014;762:123–32.PubMedGoogle Scholar
  9. 9.
    Kinney MC, Kadin ME. The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation. Am J Clin Pathol. 1999;111(1 Suppl 1):S56–67.PubMedGoogle Scholar
  10. 10.
    Swerdlow SH, World Health Organization & International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: IARC; 2017.Google Scholar
  11. 11.
    Bonzheim I, Geissinger E, Roth S, Zettl A, Marx A, Rosenwald A, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood. 2004;104(10):3358–60.PubMedGoogle Scholar
  12. 12.
    Malcolm TI, Villarese P, Fairbairn CJ, Lamant L, Trinquand A, Hook CE, et al. Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. Nat Commun. 2016;7:10087.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Hogquist KA, Jameson SC. The self-obsession of T cells: how TCR signaling thresholds affect fate ‘decisions’ and effector function. Nat Immunol. 2014;15(9):815–23.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Pearson JD, Lee JK, Bacani JT, Lai R, Ingham RJ. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma. Int J Clin Exp Pathol. 2011;4(2):124–33.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Hsu FY, Johnston PB, Burke KA, Zhao Y. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner. Cancer Res. 2006;66(18):9002–8.PubMedGoogle Scholar
  16. 16.
    Zhang Q, Wei F, Wang HY, Liu X, Roy D, Xiong QB, et al. The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes. Am J Pathol. 2013;183(6):1971–80.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026–36.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Schleussner N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, et al. The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma. Leukemia. 2018;32(9):1994–2007.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Eckerle S, Brune V, Doring C, Tiacci E, Bohle V, Sundstrom C, et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia. 2009;23(11):2129–38.PubMedGoogle Scholar
  20. 20.
    Matsuyama H, Suzuki HI, Nishimori H, Noguchi M, Yao T, Komatsu N, et al. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood. 2011;118(26):6881–92.PubMedGoogle Scholar
  21. 21.
    Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci U S A. 2006;103(26):9964–9.PubMedPubMedCentralGoogle Scholar
  22. 22.
    O’Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science. 2010;327(5969):1098–102.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Gao W, Thompson L, Zhou Q, Putheti P, Fahmy TM, Strom TB, et al. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle. 2009;8(9):1444–50.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Tripathi SK, Lahesmaa R. Transcriptional and epigenetic regulation of T-helper lineage specification. Immunol Rev. 2014;261(1):62–83.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10(6):717–28.PubMedGoogle Scholar
  27. 27.
    Moti N, Malcolm T, Hamoudi R, Mian S, Garland G, Hook CE, et al. Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin. Oncogene. 2015;34(14):1843–52.PubMedGoogle Scholar
  28. 28.
    Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005;15(9):494–501.PubMedGoogle Scholar
  29. 29.
    Vieyra DS, Rosen A, Goodell MA. Identification and characterization of side population cells in embryonic stem cell cultures. Stem Cells Dev. 2009;18(8):1155–66.PubMedGoogle Scholar
  30. 30.
    Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001;98(4):1166–73.PubMedGoogle Scholar
  31. 31.
    Piccaluga PP, Ascani S, Fraternali Orcioni G, Piccioli M, Pileri A Jr, Falini B, et al. Anaplastic lymphoma kinase expression as a marker of malignancy. Application to a case of anaplastic large cell lymphoma with huge granulomatous reaction. Haematologica. 2000;85(9):978–81.PubMedGoogle Scholar
  32. 32.
    Lamant L, Pileri S, Sabattini E, Brugieres L, Jaffe ES, Delsol G. Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases. Haematologica. 2010;95(3):449–55.PubMedGoogle Scholar
  33. 33.
    Skinner GR. Transformation of primary hamster embryo fibroblasts by type 2 simplex virus: evidence for a “hit and run” mechanism. Br J Exp Pathol. 1976;57(4):361–76.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Youssif C, Goldenbogen J, Hamoudi R, Carreras J, Viskaduraki M, Cui Y-X, et al. Genomic profiling of pediatric ALK-positive anaplastic large cell lymphoma: a children’s cancer and leukaemia group study. Genes Chromosomes Cancer. 2009;48(11):1018–26.PubMedGoogle Scholar
  35. 35.
    Salaverria I, Bea S, Lopez-Guillermo A, Lespinet V, Pinyol M, Burkhardt B, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol. 2008;140(5):516–26.PubMedGoogle Scholar
  36. 36.
    Slupianek A, Poplawski T, Jozwiakowski SK, Cramer K, Pytel D, Stoczynska E, et al. BCR/ABL stimulates WRN to promote survival and genomic instability. Cancer Res. 2011;71(3):842–51.PubMedGoogle Scholar
  37. 37.
    Rink L, Slupianek A, Stoklosa T, Nieborowska-Skorska M, Urbanska K, Seferynska I, et al. Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells. Blood. 2007;110(2):651–60.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Hoser G, Majsterek I, Romana DL, Slupianek A, Blasiak J, Skorski T. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance? Leuk Res. 2003;27(3):267–73.PubMedGoogle Scholar
  39. 39.
    Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol. 2002;22(12):4189–201.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Young LC, Bone KM, Wang P, Wu F, Adam BA, Hegazy S, et al. Fusion tyrosine kinase NPM-ALK deregulates MSH2 and suppresses DNA mismatch repair function novel insights into a potent oncoprotein. Am J Pathol. 2011;179(1):411–21.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27(4):516–32.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Zhang Q, Wang H, Kantekure K, Paterson JC, Liu X, Schaffer A, et al. Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS. Blood. 2011;118(11):3062–71.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol. 2002;168(1):466–74.PubMedGoogle Scholar
  44. 44.
    Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 2001;61(5):2194–9.PubMedGoogle Scholar
  45. 45.
    Marzec M, Liu X, Wong W, Yang Y, Pasha T, Kantekure K, et al. Oncogenic kinase NPM/ALK induces expression of HIF1alpha mRNA. Oncogene. 2011;30(11):1372–8.PubMedGoogle Scholar
  46. 46.
    Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008;105(52):20852–7.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Marzec M, Halasa K, Liu X, Wang HY, Cheng M, Baldwin D, et al. Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming. J Immunol. 2013;191(12):6200–7.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Anastasov N, Bonzheim I, Rudelius M, Klier M, Dau T, Angermeier D, et al. C/EBPbeta expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. Haematologica. 2010;95(5):760–7.PubMedGoogle Scholar
  49. 49.
    Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol. 1998;18(12):6951–61.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood. 2000;96(13):4319–27.PubMedGoogle Scholar
  51. 51.
    Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW, et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood. 2004;103(4):1464–71.PubMedGoogle Scholar
  52. 52.
    Ambrogio C, Voena C, Manazza AD, Piva R, Riera L, Barberis L, et al. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood. 2005;106(12):3907–16.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11(6):623–9.PubMedGoogle Scholar
  54. 54.
    Voena C, Conte C, Ambrogio C, Boeri Erba E, Boccalatte F, Mohammed S, et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 2007;67(9):4278–86.PubMedGoogle Scholar
  55. 55.
    Desjobert C, Renalier MH, Bergalet J, Dejean E, Joseph N, Kruczynski A, et al. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood. 2011;117(24):6627–37.PubMedGoogle Scholar
  56. 56.
    Colomba A, Giuriato S, Dejean E, Thornber K, Delsol G, Tronchere H, et al. Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination. Blood Cancer J. 2011;1(6):e21.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Dejean E, Foisseau M, Lagarrigue F, Lamant L, Prade N, Marfak A, et al. ALK+ALCLs induce cutaneous, HMGB-1-dependent IL-8/CXCL8 production by keratinocytes through NF-kappaB activation. Blood. 2012;119(20):4698–707.PubMedGoogle Scholar
  58. 58.
    Lim MS, Carlson ML, Crockett DK, Fillmore GC, Abbott DR, Elenitoba-Johnson OF, et al. The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. Blood. 2009;114(8):1585–95.PubMedGoogle Scholar
  59. 59.
    McDonnell SR, Hwang SR, Basrur V, Conlon KP, Fermin D, Wey E, et al. NPM-ALK signals through glycogen synthase kinase 3beta to promote oncogenesis. Oncogene. 2012;31(32):3733–40.PubMedGoogle Scholar
  60. 60.
    McDonnell SR, Hwang SR, Rolland D, Murga-Zamalloa C, Basrur V, Conlon KP, et al. Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma. Blood. 2013;122(6):958–68.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Turner SD, Merz H, Yeung D, Alexander DR. CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy. Anticancer Res. 2006;26(5A):3275–9.PubMedGoogle Scholar
  62. 62.
    Turner SD, Tooze R, Maclennan K, Alexander DR. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene. 2003;22(49):7750–61.PubMedGoogle Scholar
  63. 63.
    Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003;101(5):1919–27.PubMedGoogle Scholar
  64. 64.
    Riera L, Lasorsa E, Bonello L, Sismondi F, Tondat F, Di Bello C, et al. Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. Leuk Lymphoma. 2011;52(9):1742–50.PubMedGoogle Scholar
  65. 65.
    Hassler MR, Pulverer W, Lakshminarasimhan R, Redl E, Hacker J, Garland GD, et al. Insights into the pathogenesis of anaplastic large-cell lymphoma through genome-wide DNA methylation profiling. Cell Rep. 2016;17(2):596–608.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Zhang Q, Wang HY, Woetmann A, Raghunath PN, Odum N, Wasik MA. STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood. 2006;108(3):1058–64.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Laurent C, Lopez C, Desjobert C, Berrebi A, Damm-Welk C, Delsol G, et al. Circulating t(2;5)-positive cells can be detected in cord blood of healthy newborns. Leukemia. 2012;26(1):188–90.PubMedGoogle Scholar
  68. 68.
    Ambrogio C, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T, et al. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res. 2008;68(21):8899–907.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Gaud G, Lesourne R, Love PE. Regulatory mechanisms in T cell receptor signalling. Nat Rev Immunol. 2018;18(8):485–97.PubMedGoogle Scholar
  70. 70.
    Turner SD, Yeung D, Hadfield K, Cook SJ, Alexander DR. The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. Cell Signal. 2007;19(4):740–7.PubMedGoogle Scholar
  71. 71.
    Pomari E, Basso G, Bresolin S, Pillon M, Carraro E, d’Amore ES, et al. NPM-ALK expression levels identify two distinct subtypes of paediatric anaplastic large cell lymphoma. Leukemia. 2017;31(2):498–501.PubMedGoogle Scholar
  72. 72.
    Ambrogio C, Martinengo C, Voena C, Tondat F, Riera L, di Celle PF, et al. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res. 2009;69(22):8611–9.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Mjosberg J, Spits H. Human innate lymphoid cells. J Allergy Clin Immunol. 2016;138(5):1265–76.PubMedGoogle Scholar
  74. 74.
    Knorr F, Damm-Welk C, Ruf S, Singh VK, Zimmermann M, Reiter A, et al. Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Haematologica. 2018;103(3):477–85.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Cellular and Molecular Pathology, Department of PathologyUniversity of Cambridge, Addenbrooke’s HospitalCambridgeUK

Personalised recommendations